Psoriasis Therapeutics Market By Drug Class, By Type, By Route of Administration: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
3.7. Patent Landscape

CHAPTER 4: PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 TNF-alpha Inhibitors
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Interleukin Inhibitors
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.3.4 Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
4.3.4.1 Hospital Pharmacies Market size and forecast, by region
4.3.4.2 DrU.S.ores and Retail Pharmacies Market size and forecast, by region
4.3.4.3 Online Providers Market size and forecast, by region
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country

CHAPTER 5: PSORIASIS THERAPEUTICS MARKET, BY TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Plaque Psoriasis
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Psoriatic Arthritis
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country

CHAPTER 6: PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Oral
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Parenteral
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Topical
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country

CHAPTER 7: PSORIASIS THERAPEUTICS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.2.1 North America Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
7.2.3 North America Market size and forecast, by Type
7.2.4 North America Market size and forecast, by Route of Administration
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Class
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Route of Administration
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Route of Administration
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Route of Administration
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.2.1 Europe Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
7.3.3 Europe Market size and forecast, by Type
7.3.4 Europe Market size and forecast, by Route of Administration
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Route of Administration
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Route of Administration
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Route of Administration
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Route of Administration
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Route of Administration
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Route of Administration
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.2.1 Asia-Pacific Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
7.4.3 Asia-Pacific Market size and forecast, by Type
7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Route of Administration
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Route of Administration
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Drug Class
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Route of Administration
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Drug Class
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Route of Administration
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Route of Administration
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Route of Administration
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.2.1 LAMEA Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
7.5.3 LAMEA Market size and forecast, by Type
7.5.4 LAMEA Market size and forecast, by Route of Administration
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Route of Administration
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Route of Administration
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Route of Administration
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Route of Administration

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 Abbvie Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Amgen Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bausch Health Companies Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Eli Lilly and Company
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Johnson and Johnson
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 LEO Pharma
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novan Inc. (EPI Health LLC)
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Novartis AG
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Pfizer Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Viatris Inc. (Mylan NV)
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

List of Tables
Table 1. Global Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 2. Psoriasis Therapeutics Market, for Tnf-Alpha Inhibitors, by Region, 2021-2031 ($Million)
Table 3. Psoriasis Therapeutics Market for Tnf-Alpha Inhibitors, by Country, 2021-2031 ($Million)
Table 4. Psoriasis Therapeutics Market, for Interleukin Inhibitors, by Region, 2021-2031 ($Million)
Table 5. Psoriasis Therapeutics Market for Interleukin Inhibitors, by Country, 2021-2031 ($Million)
Table 6. Global Interleukin Inhibitors Psoriasis Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 7. Psoriasis Therapeutics Market, for Hospital Pharmacies, by Region, 2021-2031 ($Million)
Table 8. Psoriasis Therapeutics Market, for DrU.S.ores and Retail Pharmacies, by Region, 2021-2031 ($Million)
Table 9. Psoriasis Therapeutics Market, for Online Providers, by Region, 2021-2031 ($Million)
Table 10. Psoriasis Therapeutics Market, for Others, by Region, 2021-2031 ($Million)
Table 11. Psoriasis Therapeutics Market for Others, by Country, 2021-2031 ($Million)
Table 12. Global Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 13. Psoriasis Therapeutics Market, for Plaque Psoriasis, by Region, 2021-2031 ($Million)
Table 14. Psoriasis Therapeutics Market for Plaque Psoriasis, by Country, 2021-2031 ($Million)
Table 15. Psoriasis Therapeutics Market, for Psoriatic Arthritis, by Region, 2021-2031 ($Million)
Table 16. Psoriasis Therapeutics Market for Psoriatic Arthritis, by Country, 2021-2031 ($Million)
Table 17. Psoriasis Therapeutics Market, for Others, by Region, 2021-2031 ($Million)
Table 18. Psoriasis Therapeutics Market for Others, by Country, 2021-2031 ($Million)
Table 19. Global Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 20. Psoriasis Therapeutics Market, for Oral, by Region, 2021-2031 ($Million)
Table 21. Psoriasis Therapeutics Market for Oral, by Country, 2021-2031 ($Million)
Table 22. Psoriasis Therapeutics Market, for Parenteral, by Region, 2021-2031 ($Million)
Table 23. Psoriasis Therapeutics Market for Parenteral, by Country, 2021-2031 ($Million)
Table 24. Psoriasis Therapeutics Market, for Topical, by Region, 2021-2031 ($Million)
Table 25. Psoriasis Therapeutics Market for Topical, by Country, 2021-2031 ($Million)
Table 26. Psoriasis Therapeutics Market, by Region, 2021-2031 ($Million)
Table 27. North America Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 28. North America Interleukin Inhibitors Psoriasis Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 29. North America Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 30. North America Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 31. North America Psoriasis Therapeutics Market, by Country, 2021-2031 ($Million)
Table 32. U.S. Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 33. U.S. Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 34. U.S. Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 35. Canada Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 36. Canada Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 37. Canada Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 38. Mexico Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 39. Mexico Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 40. Mexico Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 41. Europe Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 42. Europe Interleukin Inhibitors Psoriasis Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 43. Europe Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 44. Europe Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 45. Europe Psoriasis Therapeutics Market, by Country, 2021-2031 ($Million)
Table 46. Germany Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 47. Germany Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 48. Germany Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 49. France Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 50. France Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 51. France Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 52. UK Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 53. UK Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 54. UK Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 55. Italy Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 56. Italy Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 57. Italy Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 58. Spain Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 59. Spain Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 60. Spain Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 61. Rest of Europe Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 62. Rest of Europe Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 63. Rest of Europe Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 64. Asia-Pacific Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 65. Asia-Pacific Interleukin Inhibitors Psoriasis Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 66. Asia-Pacific Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 67. Asia-Pacific Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 68. Asia-Pacific Psoriasis Therapeutics Market, by Country, 2021-2031 ($Million)
Table 69. Japan Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 70. Japan Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 71. Japan Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 72. China Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 73. China Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 74. China Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 75. India Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 76. India Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 77. India Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 78. Australia Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 79. Australia Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 80. Australia Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 81. South Korea Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 82. South Korea Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 83. South Korea Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 84. Rest of Asia-Pacific Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 85. Rest of Asia-Pacific Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 86. Rest of Asia-Pacific Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 87. LAMEA Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 88. LAMEA Interleukin Inhibitors Psoriasis Therapeutics Market, by Distribution Channel, 2021-2031 ($Million)
Table 89. LAMEA Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 90. LAMEA Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 91. LAMEA Psoriasis Therapeutics Market, by Country, 2021-2031 ($Million)
Table 92. Brazil Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 93. Brazil Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 94. Brazil Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 95. Saudi Arabia Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 96. Saudi Arabia Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 97. Saudi Arabia Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 98. South Africa Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 99. South Africa Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 100. South Africa Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 101. Rest of LAMEA Psoriasis Therapeutics Market, by Drug Class, 2021-2031 ($Million)
Table 102. Rest of LAMEA Psoriasis Therapeutics Market, by Type, 2021-2031 ($Million)
Table 103. Rest of LAMEA Psoriasis Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 104. Abbvie Inc.: Company Snapshot
Table 105. Abbvie Inc.: Operating Segments
Table 106. Abbvie Inc.: Product Portfolio
Table 107. Abbvie Inc.: Net Sales
Table 108. Abbvie Inc.: Key Strategies
Table 109. Amgen Inc.: Company Snapshot
Table 110. Amgen Inc.: Operating Segments
Table 111. Amgen Inc.: Product Portfolio
Table 112. Amgen Inc.: Net Sales
Table 113. Amgen Inc.: Key Strategies
Table 114. Bausch Health Companies Inc.: Company Snapshot
Table 115. Bausch Health Companies Inc.: Operating Segments
Table 116. Bausch Health Companies Inc.: Product Portfolio
Table 117. Bausch Health Companies Inc.: Net Sales
Table 118. Bausch Health Companies Inc.: Key Strategies
Table 119. Eli Lilly and Company: Company Snapshot
Table 120. Eli Lilly and Company: Operating Segments
Table 121. Eli Lilly and Company: Product Portfolio
Table 122. Eli Lilly and Company: Net Sales
Table 123. Eli Lilly and Company: Key Strategies
Table 124. Johnson and Johnson: Company Snapshot
Table 125. Johnson and Johnson: Operating Segments
Table 126. Johnson and Johnson: Product Portfolio
Table 127. Johnson and Johnson: Net Sales
Table 128. Johnson and Johnson: Key Strategies
Table 129. Leo Pharma: Company Snapshot
Table 130. Leo Pharma: Operating Segments
Table 131. Leo Pharma: Product Portfolio
Table 132. Leo Pharma: Net Sales
Table 133. Leo Pharma: Key Strategies
Table 134. Novan Inc. (Epi Health LLC): Company Snapshot
Table 135. Novan Inc. (Epi Health LLC): Operating Segments
Table 136. Novan Inc. (Epi Health LLC): Product Portfolio
Table 137. Novan Inc. (Epi Health LLC): Net Sales
Table 138. Novan Inc. (Epi Health LLC): Key Strategies
Table 139. Novartis AG: Company Snapshot
Table 140. Novartis AG: Operating Segments
Table 141. Novartis AG: Product Portfolio
Table 142. Novartis AG: Net Sales
Table 143. Novartis AG: Key Strategies
Table 144. Pfizer Inc.: Company Snapshot
Table 145. Pfizer Inc.: Operating Segments
Table 146. Pfizer Inc.: Product Portfolio
Table 147. Pfizer Inc.: Net Sales
Table 148. Pfizer Inc.: Key Strategies
Table 149. Viatris Inc. (Mylan Nv): Company Snapshot
Table 150. Viatris Inc. (Mylan Nv): Operating Segments
Table 151. Viatris Inc. (Mylan Nv): Product Portfolio
Table 152. Viatris Inc. (Mylan Nv): Net Sales
Table 153. Viatris Inc. (Mylan Nv): Key Strategies

List of Figures
Figure 1. Psoriasis Therapeutics Market Segmentation
Figure 2. Psoriasis Therapeutics Market, 2021-2031
Figure 3. Psoriasis Therapeutics Market, 2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Psoriasis Therapeutics Mark.:Drivers, Restraints and Opportunities
Figure 12. Patent Analysis by Company
Figure 13. Patent Analysis by Country
Figure 14. Psoriasis Therapeutics Market, By Drug Class, 2021(%)
Figure 15. Comparative Share Analysis of Tnf-Alpha Inhibitors Psoriasis Therapeutics Market, 2021-2031(%)
Figure 16. Comparative Share Analysis of Interleukin Inhibitors Psoriasis Therapeutics Market, 2021-2031(%)
Figure 17. Comparative Share Analysis of Others Psoriasis Therapeutics Market, 2021-2031(%)
Figure 18. Psoriasis Therapeutics Market, By Type, 2021(%)
Figure 19. Comparative Share Analysis of Plaque Psoriasis Psoriasis Therapeutics Market, 2021-2031(%)
Figure 20. Comparative Share Analysis of Psoriatic Arthritis Psoriasis Therapeutics Market, 2021-2031(%)
Figure 21. Comparative Share Analysis of Others Psoriasis Therapeutics Market, 2021-2031(%)
Figure 22. Psoriasis Therapeutics Market, By Route of Administration, 2021(%)
Figure 23. Comparative Share Analysis of Oral Psoriasis Therapeutics Market, 2021-2031(%)
Figure 24. Comparative Share Analysis of Parenteral Psoriasis Therapeutics Market, 2021-2031(%)
Figure 25. Comparative Share Analysis of Topical Psoriasis Therapeutics Market, 2021-2031(%)
Figure 26. Psoriasis Therapeutics Market by Region, 2021
Figure 27. U.S. Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 28. Canada Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 29. Mexico Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 30. Germany Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 31. France Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 32. Uk Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 33. Italy Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 34. Spain Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 35. Rest of Europe Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 36. Japan Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 37. China Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 38. India Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 39. Australia Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 40. South Korea Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 41. Rest of Asia-Pacific Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 42. Brazil Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 43. Saudi Arabia Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 44. South Africa Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 45. Rest of LAMEA Psoriasis Therapeutics Market, 2021-2031($Million)
Figure 46. Top Winning Strategies, by Year
Figure 47. Top Winning Strategies, by Development
Figure 48. Top Winning Strategies, by Company
Figure 49. Product Mapping of Top 10 Players
Figure 50. Competitive Dashboard
Figure 51. Competitive Heatmap of Top 10 Key Players
Figure 52. Abbvie Inc.: Net Sales, ($Million)
Figure 53. Amgen Inc.: Net Sales, ($Million)
Figure 54. Bausch Health Companies Inc.: Net Sales, ($Million)
Figure 55. Eli Lilly and Compan.: Net Sales, ($Million)
Figure 56. Johnson and Johnso.: Net Sales, ($Million)
Figure 57. Leo Pharm.: Net Sales, ($Million)
Figure 58. Novan Inc. (Epi Health LLC.: Net Sales, ($Million)
Figure 59. Novartis A.: Net Sales, ($Million)
Figure 60. Pfizer Inc.: Net Sales, ($Million)
Figure 61. Viatris Inc. (Mylan Nv.: Net Sales, ($Million)

Executive Summary

According to the report, “Psoriasis Therapeutics Market," the psoriasis therapeutics market size was valued at $22.9 billion in 2021, and is estimated to reach $55.8 billion by 2031, growing at a CAGR of 9.3% from 2022 to 2031.

Psoriasis is a skin condition that typically affects knees, elbows, trunk, and scalp. It generates a rash with itchy, scaly spots. Psoriasis is a frequent, chronic condition that has no cure. It may hurt, keep patients up at night, and difficult to focus on. The illness frequently goes through cycles where it will flare up for a few weeks or months before decreasing. Infections, cuts, burns, and specific drugs are common psoriasis triggers in persons with a hereditary predisposition to the condition.

Treatments for psoriasis include oral or injectable drugs, light therapy, phototherapy, and lotions and ointments (topical therapy). The severity of psoriasis and how responsive it has been to prior therapies and self-care techniques can influence patient's choice of treatments. Before finding a strategy that works, patient might need to test out other medications or a combination of treatments. The condition typically reappears even after a successful treatment.

Psoriasis therapeutics market trends that drive growth of the market is increase in geriatric population, growing prevalence of plaque and psoriatic arthritis, favorable reimbursement policies, and rise in prescription volume of biological products. In addition, rise in awareness among people regarding different treatments available in the market is further expected to boost the market growth during forecast period.

However, health risks posed due to medication along with high costs of therapies is expected to hamper the growth of psoriasis therapeutics market size during the forecast period. Moreover, increasing development of new biologics and novel pipeline drugs and high growth potential in untapped emerging countries are expected to provide numerous opportunities for the market growth during the forecast period.

By drug class, the interleukin inhibitor segment dominated the market in 2021, and is expected to remain dominant during psoriasis therapeutics market forecast. This is attributed to increase in number of research trials being conducted across the globe to evaluate efficiency of these drugs in treatment of this disease propel the market growth during the forecast period. Moreover, increase in prevalence of chronic inflammatory diseases such as arthritis, psoriasis, and asthma are anticipated to fuel growth of the market.

Depending on type, the plaque psoriasis segment dominated the market in 2021, and is expected to remain dominant during psoriasis therapeutics market analysis, owing to growing number of novel and innovative products for treatment of this disorder type by various key players are expected to fuel the plaque psoriasis segment growth during the forecast period.

On the basis of route of administration, the parenteral segment was the major revenue contributor in 2021, and is anticipated to continue this trend during the forecast period, owing to rise in adoption of biologics and surge in approval of biologics are expected to propel the parenteral segment.

Region wise, North America has the highest psoriasis therapeutics market share in 2021 registering a CAGR of 8.1% during the forecast period. This is attributed to factors such as presence of large population base and rise in patient pool in countries such as the U.S., Moreover, high disposable income among people in North America has driven development in the healthcare industry, owing to affordability to invest in highly advanced medication that meets the targeted medical need of the people which further drive the market growth in the region.

However, Asia-Pacific is projected to register the highest CAGR of 12.0% in psoriasis therapeutics industry during the forecast period. This is attributed to increase in awareness toward psoriasis therapeutics and rise in adoption of psoriasis therapeutics products. Furthermore, improvements in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, development of the R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare are the key driving factors that boost growth of the market in the region.

Key Findings of the Study

• On the basis of drug class, the interleukin inhibitors segment dominated the psoriasis therapeutics industry in 2021, and is expected to continue this trend during the forecast period.
• On the basis of type, the plaque psoriasis segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
• On the basis of route of administration, the parenteral segment dominated the market in 2021, and is expected to continue this trend during the forecast period.

•Region-wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 12.0% during the forecast period.

Companies Mentioned

• Abbvie Inc.
• Amgen Inc.
• Bausch Health Companies Inc.
• Eli Lilly and Company
• Johnson and Johnson
• LEO Pharma
• Novan Inc. (EPI Health LLC)
• Novartis AG
• Pfizer Inc.
• Viatris Inc. (Mylan NV)

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.